The Added Value of Diagnostic and Theranostic PET Imaging for the Treatment of CNS Tumors

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2020 Feb 9

PMID 32033160

Citations 12

Authors

Ilanah J Pruis

Guus A M S van Dongen

Sophie E M Veldhuijzen van Zanten

Affiliations

Soon will be listed here.

Abstract

This review highlights the added value of PET imaging in Central Nervous System (CNS) tumors, which is a tool that has rapidly evolved from a merely diagnostic setting to multimodal molecular diagnostics and the guidance of targeted therapy. PET is the method of choice for studying target expression and target binding behind the assumedly intact blood-brain barrier. Today, a variety of diagnostic PET tracers can be used for the primary staging of CNS tumors and to determine the effect of therapy. Additionally, theranostic PET tracers are increasingly used in the context of pharmaceutical and radiopharmaceutical drug development and application. In this approach, a single targeted drug is used for PET diagnosis, upon the coupling of a PET radionuclide, as well as for targeted (nuclide) therapy. Theranostic PET tracers have the potential to serve as a non-invasive whole body navigator in the selection of the most effective drug candidates and their most optimal dose and administration route, together with the potential to serve as a predictive biomarker in the selection of patients who are most likely to benefit from treatment. PET imaging supports the transition from trial and error medicine to predictive, preventive, and personalized medicine, hopefully leading to improved quality of life for patients and more cost-effective care.

Citing Articles

Comparison of PET/CT and PET/MRI in central nervous system tumors, a narrative review.

Riahi F, Kiani P, Golabbakhsh A, Khanezarrin M, Abbaspour M, Tabatabaei S Int J Physiol Pathophysiol Pharmacol. 2024; 16(4):89-95.

PMID: 39310737 PMC: 11411248. DOI: 10.62347/UMDS1961.

Clinical Theranostics in Recurrent Gliomas: A Review.

Hoggarth A, Muthukumar S, Thomas S, Crowley J, Kiser J, Witcher M Cancers (Basel). 2024; 16(9).

PMID: 38730666 PMC: 11083317. DOI: 10.3390/cancers16091715.

Elevating theranostics: The emergence and promise of radiopharmaceutical cell-targeting heterodimers in human cancers.

Chambers C, Chitwood B, Smith C, Miao Y iRadiology. 2024; 2(2):128-155.

PMID: 38708130 PMC: 11067702. DOI: 10.1002/ird3.62.

Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation.

Dhoundiyal S, Srivastava S, Kumar S, Singh G, Ashique S, Pal R Eur J Med Res. 2024; 29(1):26.

PMID: 38183131 PMC: 10768149. DOI: 10.1186/s40001-023-01627-0.

Dual-Peak Lorentzian CEST MRI for antiretroviral drug brain distribution.

Liu Y, Gauthier G, Gendelman H, Bade A NeuroImmune Pharm Ther. 2023; 2(1):63-69.

PMID: 37027345 PMC: 10070014. DOI: 10.1515/nipt-2022-0012.

References

Patronas N, DI CHIRO G, Kufta C, Bairamian D, KORNBLITH P, Simon R . Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg. 1985; 62(6):816-22. DOI: 10.3171/jns.1985.62.6.0816. View

Zikou A, Sioka C, Alexiou G, Fotopoulos A, Voulgaris S, Argyropoulou M . Radiation Necrosis, Pseudoprogression, Pseudoresponse, and Tumor Recurrence: Imaging Challenges for the Evaluation of Treated Gliomas. Contrast Media Mol Imaging. 2019; 2018:6828396. PMC: 6305027. DOI: 10.1155/2018/6828396. View

Xiangsong Z, Xingchong S, Chang Y, Xiaoyan W, Zhifeng C . 13N-NH3 versus F-18 FDG in detection of intracranial meningioma: initial report. Clin Nucl Med. 2011; 36(11):1003-6. DOI: 10.1097/RLU.0b013e3182291c2a. View

Krolicki L, Bruchertseifer F, Kunikowska J, Koziara H, Krolicki B, Jakucinski M . Prolonged survival in secondary glioblastoma following local injection of targeted alpha therapy with Bi-substance P analogue. Eur J Nucl Med Mol Imaging. 2018; 45(9):1636-1644. PMC: 6061489. DOI: 10.1007/s00259-018-4015-2. View

Sasikumar A, Joy A, Pillai M, Nanabala R, Anees K M, Jayaprakash P . Diagnostic Value of 68Ga PSMA-11 PET/CT Imaging of Brain Tumors-Preliminary Analysis. Clin Nucl Med. 2016; 42(1):e41-e48. DOI: 10.1097/RLU.0000000000001451. View

Nomura N, Pastorino S, Jiang P, Lambert G, Crawford J, Gymnopoulos M . Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases. Cancer Cell Int. 2014; 14(1):26. PMC: 3994554. DOI: 10.1186/1475-2867-14-26. View

Weber B, Winterdahl M, Memon A, Sorensen B, Keiding S, Sorensen L . Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor. J Thorac Oncol. 2011; 6(7):1287-9. DOI: 10.1097/JTO.0b013e318219ab87. View

Jorgensen J, Hersom M . Companion diagnostics-a tool to improve pharmacotherapy. Ann Transl Med. 2017; 4(24):482. PMC: 5233535. DOI: 10.21037/atm.2016.12.26. View

Varrone A, Varnas K, Jucaite A, Cselenyi Z, Johnstrom P, Schou M . A PET study in healthy subjects of brain exposure of C-labelled osimertinib - A drug intended for treatment of brain metastases in non-small cell lung cancer. J Cereb Blood Flow Metab. 2019; 40(4):799-807. PMC: 7168784. DOI: 10.1177/0271678X19843776. View

10.

Postema E, McEwan A, Riauka T, Kumar P, Richmond D, Abrams D . Initial results of hypoxia imaging using 1-alpha-D: -(5-deoxy-5-[18F]-fluoroarabinofuranosyl)-2-nitroimidazole ( 18F-FAZA). Eur J Nucl Med Mol Imaging. 2009; 36(10):1565-73. DOI: 10.1007/s00259-009-1154-5. View

11.

Bertram J . The molecular biology of cancer. Mol Aspects Med. 2001; 21(6):167-223. DOI: 10.1016/s0098-2997(00)00007-8. View

12.

Kunikowska J, Bartosz K, Leszek K . Glioblastoma multiforme: another potential application for Ga-PSMA PET/CT as a guide for targeted therapy. Eur J Nucl Med Mol Imaging. 2018; 45(5):886-887. DOI: 10.1007/s00259-018-3934-2. View

13.

Su Z, Herholz K, Gerhard A, Roncaroli F, du Plessis D, Jackson A . [¹¹C]-(R)PK11195 tracer kinetics in the brain of glioma patients and a comparison of two referencing approaches. Eur J Nucl Med Mol Imaging. 2013; 40(9):1406-19. PMC: 3738844. DOI: 10.1007/s00259-013-2447-2. View

14.

Zhu Y, Zhu X . MRI-Driven PET Image Optimization for Neurological Applications. Front Neurosci. 2019; 13:782. PMC: 6684790. DOI: 10.3389/fnins.2019.00782. View

15.

Montes A, Fernandez A, Camacho V, de Quintana C, Gallego O, Craven-Bartle J . The usefulness of 18F-fluorocholine PET/CT in the detection of recurrence of central nervous system primary neoplasms. Rev Esp Med Nucl Imagen Mol. 2017; 36(4):227-232. DOI: 10.1016/j.remn.2016.11.005. View

16.

Saleem A, Searle G, Kenny L, Huiban M, Kozlowski K, Waldman A . Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer. EJNMMI Res. 2015; 5:30. PMC: 4424224. DOI: 10.1186/s13550-015-0103-5. View

17.

Yamamoto Y, Nishiyama Y, Kimura N, Kameyama R, Kawai N, Hatakeyama T . 11C-acetate PET in the evaluation of brain glioma: comparison with 11C-methionine and 18F-FDG-PET. Mol Imaging Biol. 2008; 10(5):281-7. DOI: 10.1007/s11307-008-0152-5. View

18.

Lesniak W, Chu C, Jablonska A, Du Y, Pomper M, Walczak P . A Distinct Advantage to Intraarterial Delivery of Zr-Bevacizumab in PET Imaging of Mice With and Without Osmotic Opening of the Blood-Brain Barrier. J Nucl Med. 2018; 60(5):617-622. PMC: 6495238. DOI: 10.2967/jnumed.118.218792. View

19.

Narayanaswami V, Dahl K, Bernard-Gauthier V, Josephson L, Cumming P, Vasdev N . Emerging PET Radiotracers and Targets for Imaging of Neuroinflammation in Neurodegenerative Diseases: Outlook Beyond TSPO. Mol Imaging. 2018; 17:1536012118792317. PMC: 6134492. DOI: 10.1177/1536012118792317. View

20.

Poli G, Bianchi C, Virotta G, Bettini A, Moretti R, Trachsel E . Radretumab radioimmunotherapy in patients with brain metastasis: a 124I-L19SIP dosimetric PET study. Cancer Immunol Res. 2014; 1(2):134-43. DOI: 10.1158/2326-6066.CIR-13-0007. View